In The News

OVA1, Ovarian Cancer Blood Test, Not a General Screening Test

The Ovarian Cancer National Alliance has released the following statement clarifying the limited use of OVA1: "A new risk assessment test for ovarian cancer, OVA1, is now available. Vermillion's OVA1 test, available only through Quest Diagnostics, Inc., is the first blood test approved by the U.S. Food and Drug Administration (FDA) to help physicians determine the likelihood that a woman's ovarian mass is cancerous or not, prior to a planned surgery.

OVA1 measures the levels of five protein biomarkers in a woman's blood to determine the likelihood of cancer. Approximately 20 percent of women with pelvic masses have cancer, but the proportion rises with age. The results of the test may help a physician decide the type of surgeon who should operate on a patient with a pelvic mass. Data shows that women with ovarian cancer who have their surgeries performed by a gynecologic oncologist fare better, however, many women have their initial surgery performed by a gynecologist.

OVA1 is not a screening test for ovarian cancer. A physician should use the test along with clinical exams and other tests."

For more information, see www.questdiagnostics.com/cancerdiagnostics/womenscancers.html


Dasatinib Plus Standard Chemo ShowsPromise for Some Ovarian Cancers

The addition of a chemotherapeutic drug for leukemia to a standard regimen of two other chemotherapy drugs appears to enhance the response of certain ovarian cancers to treatment, according to a pre-clinical study led by researchers at the Duke Comprehensive Cancer Center.

[from EurekaAlert, April 19, 2009. For background on Src see http://www.biochemsoctrans.org/bst/030/0011/0300011.pdf]


Drug Combo Helps with Repeat Uterine and Ovarian Cancers

Combined treatment with topotecan (Hycamtin) and docetaxel (Taxotere) is effective for women who have had a return of their uterine or ovarian cancer and have already been treated with other drug combinations, new research shows.

[from Reuters, reporting on Gynecologic Oncology, April 21, 2009 online]

 

 

Thank you to our supporters!